 Many research groups have been focusing efforts on developing algorithms which detect CMVs or copy number variants from whole exome sequencing data. And these research groups have benchmarked their algorithms on research or control samples and these give great insights into the reliability and sensitivity of these algorithms. But these are yet less suitable for evaluating their clinical utility. We performed whole exome sequencing on 10 patients with known pathogenic CMVs. These were 12 in total and we also performed two additional high-resolution microarray experiments on these samples to serve as an independent validation of our whole exome sequencing calls but also to study the breakpoint accuracy of whole exome sequencing approaches. From our results we see that there was one algorithm which performed best that was conifer developed by a group of avanitlur and this algorithm detected 11 of the 12 pathogenic CMVs and the one CMV which was missed represented a single exome event, deletion event. So this was particularly hard to detect. Also we see that from all the rare coding events in these patients containing three or more exomes 88% was picked up and if we extrapolate that onto the CMVs which are detected by routine medium resolution microarray screening we see that about 96% of all clinic relevant CMVs that we currently detect would have been detected by this algorithm. So we conclude that CMV detection from whole exome sequencing is applicable in a clinical setting. So CMV detection from whole exome sequencing data can improve diagnostic yield and is especially valuable when no prior screening has been performed on microarrays and as the detection methods get better and as they get combined with point mutation and indel detection these methods might start to be implemented as a single genetic test in a clinical practice and we hope that you enjoy reading with it.